Citadel Advisors’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-3,500
| Closed | -$662K | – | 13668 |
|
|
2025
Q4 | $662K | Buy |
+3,500
| New | +$673K | ﹤0.01% | 8336 |
|
|
2025
Q2 | – | Sell |
-4,600
| Closed | -$484K | – | 13944 |
|
|
2025
Q1 | $484K | Sell |
4,600
-100
| -2% | -$11.3K | ﹤0.01% | 8545 |
|
|
2024
Q4 | $504K | Sell |
4,700
-1,800
| -28% | -$203K | ﹤0.01% | 8539 |
|
|
2024
Q3 | $651K | Buy |
6,500
+5,300
| +442% | +$534K | ﹤0.01% | 7705 |
|
|
2024
Q2 | $101K | Sell |
1,200
-4,900
| -80% | -$390K | ﹤0.01% | 10906 |
|
|
2024
Q1 | $446K | Sell |
6,100
-1,800
| -23% | -$133K | ﹤0.01% | 8644 |
|
|
2023
Q4 | $564K | Sell |
7,900
-400
| -5% | -$23.6K | ﹤0.01% | 7829 |
|
|
2023
Q3 | $497K | Sell |
8,300
-700
| -8% | -$46.1K | ﹤0.01% | 8082 |
|
|
2023
Q2 | $649K | Buy |
9,000
+7,500
| +500% | +$563K | ﹤0.01% | 7367 |
|
|
2023
Q1 | $110K | Sell |
1,500
-900
| -38% | -$64K | ﹤0.01% | 11112 |
|
|
2022
Q4 | $160K | Sell |
2,400
-4,814
| -67% | -$313K | ﹤0.01% | 10503 |
|
|
2022
Q3 | $388K | Buy |
7,214
+481
| +7% | +$28.3K | ﹤0.01% | 9010 |
|
|
2022
Q2 | $375K | Sell |
6,733
-3,526
| -34% | -$200K | ﹤0.01% | 9290 |
|
|
2022
Q1 | $720K | Sell |
10,259
-4,168
| -29% | -$302K | ﹤0.01% | 8500 |
|
|
2021
Q4 | $1.39M | Sell |
14,427
-5,771
| -29% | -$533K | ﹤0.01% | 7064 |
|
|
2021
Q3 | $1.75M | Buy |
20,198
+3,527
| +21% | +$273K | ﹤0.01% | 6701 |
|
|
2021
Q2 | $1.36M | Sell |
16,671
-86,883
| -84% | -$7.23M | ﹤0.01% | 7545 |
|
|
2021
Q1 | $9.85M | Buy |
103,554
+21,480
| +26% | +$2.03M | ﹤0.01% | 2982 |
|
|
2020
Q4 | $5.09M | Buy |
82,074
+48,892
| +147% | +$2.79M | ﹤0.01% | 3653 |
|
|
2020
Q3 | $1.97M | Sell |
33,182
-6,092
| -16% | -$416K | ﹤0.01% | 4739 |
|
|
2020
Q2 | $2.74M | Buy |
39,274
+18,756
| +91% | +$1.19M | ﹤0.01% | 4018 |
|
|
2020
Q1 | $931K | Sell |
20,518
-802
| -4% | -$45.5K | ﹤0.01% | 5472 |
|
|
2019
Q4 | $1.39M | Sell |
21,320
-20,839
| -49% | -$1.39M | ﹤0.01% | 5005 |
|
|
2019
Q3 | $2.62M | Buy |
42,159
+11,862
| +39% | +$745K | ﹤0.01% | 4059 |
|
|
2019
Q2 | $2.16M | Sell |
30,297
-54,983
| -64% | -$4.05M | ﹤0.01% | 4394 |
|
|
2019
Q1 | $6.69M | Buy |
85,280
+32,221
| +61% | +$2.44M | ﹤0.01% | 2584 |
|
|
2018
Q4 | $4.49M | Buy |
53,059
+30,777
| +138% | +$3.28M | ﹤0.01% | 2940 |
|
|
2018
Q3 | $3.81M | Sell |
22,282
-9,938
| -31% | -$1.5M | ﹤0.01% | 3360 |
|
|
2018
Q2 | $4.16M | Sell |
32,220
-2,245
| -7% | -$251K | ﹤0.01% | 3014 |
|
|
2018
Q1 | $3.55M | Buy |
34,465
+22,122
| +179% | +$2.19M | ﹤0.01% | 2903 |
|
|
2017
Q4 | $1.05M | Buy |
12,343
+2,725
| +28% | +$236K | ﹤0.01% | 4582 |
|
|
2017
Q3 | $817K | Sell |
9,618
-4,008
| -29% | -$317K | ﹤0.01% | 4600 |
|
|
2017
Q2 | $1.03M | Buy |
13,626
+8,015
| +143% | +$561K | ﹤0.01% | 4037 |
|
|
2017
Q1 | $370K | Sell |
5,611
-1,122
| -17% | -$73.8K | ﹤0.01% | 5545 |
|
|
2016
Q4 | $427K | Sell |
6,733
-9,778
| -59% | -$617K | ﹤0.01% | 5154 |
|
|
2016
Q3 | $1.05M | Buy |
16,511
+962
| +6% | +$70.6K | ﹤0.01% | 3774 |
|
|
2016
Q2 | $1.16M | Buy |
15,549
+962
| +7% | +$71.4K | ﹤0.01% | 3387 |
|
|
2016
Q1 | $975K | Buy |
14,587
+1,282
| +10% | +$77.9K | ﹤0.01% | 3522 |
|
|
2015
Q4 | $900K | Buy |
13,305
+3,046
| +30% | +$188K | ﹤0.01% | 3706 |
|
|
2015
Q3 | $548K | Sell |
10,259
-14,267
| -58% | -$866K | ﹤0.01% | 4679 |
|
|
2015
Q2 | $1.54M | Buy |
24,526
+160
| +0.7% | +$8.73K | ﹤0.01% | 3368 |
|
|
2015
Q1 | $1.17M | Buy |
24,366
+15,389
| +171% | +$590K | ﹤0.01% | 3738 |
|
|
2014
Q4 | $298K | Sell |
8,977
-22,762
| -72% | -$740K | ﹤0.01% | 5440 |
|
|
2014
Q3 | $930K | Sell |
31,739
-4,168
| -12% | -$138K | ﹤0.01% | 3787 |
|
|
2014
Q2 | $1.4M | Sell |
35,907
-5,450
| -13% | -$221K | ﹤0.01% | 3097 |
|
|
2014
Q1 | $1.74M | Buy |
+41,357
| New | +$1.72M | ﹤0.01% | 2805 |
|
Other funds holding LGND
VPM
VCM
NAMI
CC
Citadel Advisors's LGND Position: Q1 2026 in Review
Citadel Advisors increased its Ligand Pharmaceuticals (LGND) stake by 219% in Q1 2026, buying an estimated $896K and bringing the position to 6,596 shares worth $1.32M. The position accounts for ﹤0.01% of the portfolio, ranked #7037.
Citadel Advisors first reported a position in LGND in Q3 2013 and has held it in 43 quarters since. The position peaked at $21.6M in Q3 2020. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.
- Citadel Advisors held 6,596 shares of Ligand Pharmaceuticals worth $1.32M as of Q1 2026.
- Citadel Advisors bought 4,530 Ligand Pharmaceuticals shares in Q1 2026, an estimated $896K.
- Ligand Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #7037 holding.
- Citadel Advisors first reported a position in Ligand Pharmaceuticals in Q3 2013 and has held it in 43 quarters since.
- Citadel Advisors's Ligand Pharmaceuticals position peaked at $21.6M in Q3 2020.
- 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.